NASDAQ:NVAX - Get Free Report ) will release its earnings data before the market opens on Friday, May 10th. Analysts expect Novavax to post earnings of ($1.04) per share for the quarter. Novavax has set its Q1 2024 guidance at EPS and its FY 2024 guidance at EPS.Individual interested in participating in the company's earnings conference call can do so using this link .
Get Novavax alerts:
Sign Up
Novavax (NASDAQ:NVAX - Get Free Report ) last posted its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.95). The firm had revenue of $291.34 million during the quarter, compared to analyst estimates of $310.96 million. During the same quarter in the prior year, the company earned ($2.28) EPS. The firm's revenue was down 18.5% compared to the same quarter last year. On average, analysts expect Novavax to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Novavax Stock Performance NVAX traded down $0.14 during midday trading on Wednesday, reaching $4.47. 3,077,201 shares of the company were exchanged, compared to its average volume of 7,120,531. The stock has a market capitalization of $627.60 million, a P/E ratio of -0.82 and a beta of 1.63. The stock's 50-day simple moving average is $4.67 and its 200 day simple moving average is $4.99. Novavax has a one year low of $3.53 and a one year high of $11.36.
Wall Street Analyst Weigh In Separately, HC Wainwright lowered their target price on shares of Novavax from $35.00 to $19.00 and set a "buy" rating for the company in a research note on Friday, March 1st.
Check Out Our Latest Report on NVAX
About Novavax (
Get Free Report )
Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
Featured Articles
Before you consider Novavax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novavax wasn't on the list.
While Novavax currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
